ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Synthetic Biologics Announces Positive FDA Meeting on SYN-004 Development
November 29, 2018Synthetic Biologics announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 ...... -
SYN-004 Receives Breakthrough Therapy Designation from FDA
May 12, 2017Synthetic Biologics announced the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) for the prevention of Clostridium difficile infection.
Pharma Sources Insight January 2025
